Fernando L Martin

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure
    Fernando L Martin
    Cardiorenal Research Laboratory, The Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Kidney Int 67:1723-30. 2005
  2. pmc The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 57:201-7. 2011
  3. pmc Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 302:R292-9. 2012
  4. ncbi request reprint Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Gugg 9 01, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 293:R1580-5. 2007
  5. pmc B-type natriuretic peptide: beyond a diagnostic
    Fernando L Martin
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Heart Fail Clin 4:449-54. 2008
  6. pmc A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 56:1152-9. 2010
  7. pmc CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e52422. 2012
  8. pmc Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Div of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Am J Physiol Renal Physiol 301:F943-52. 2011
  9. pmc A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 54:1024-32. 2009
  10. pmc Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats
    Alessandro Cataliotti
    Molecular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Circulation 123:1297-305. 2011

Detail Information

Publications20

  1. ncbi request reprint Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure
    Fernando L Martin
    Cardiorenal Research Laboratory, The Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Kidney Int 67:1723-30. 2005
    ..We also hypothesized that chronic NEPI during progressive CHF (PCHF) would improve the natriuretic response to acute volume expansion...
  2. pmc The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 57:201-7. 2011
    ..Together, these studies provide new insights into myocardial aging and the relationship to the antifibrotic and antiproliferative peptide CNP...
  3. pmc Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 302:R292-9. 2012
    ..Thus, these studies importantly advance the concept of a kidney-heart connection in the control of myocardial structure and function...
  4. ncbi request reprint Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Gugg 9 01, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 293:R1580-5. 2007
    ..These studies have both physiological and therapeutic implications warranting further research into cardiorenal interactions in this syndrome of AHF...
  5. pmc B-type natriuretic peptide: beyond a diagnostic
    Fernando L Martin
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Heart Fail Clin 4:449-54. 2008
    ....
  6. pmc A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 56:1152-9. 2010
    ..These results suggest that M-ANP, which is more potent than ANP in normal canines, has potent blood pressure lowering and renal enhancing properties and may, therefore, serve as an ANP based therapeutic for acute hypertension...
  7. pmc CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e52422. 2012
    ..Taken together, this novel dual GC receptor activator may represent an innovative anti-fibrotic therapeutic agent...
  8. pmc Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Div of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Am J Physiol Renal Physiol 301:F943-52. 2011
    ....
  9. pmc A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 54:1024-32. 2009
    ..We sought to determine the physiologic actions and potential therapeutic applications of mutant atrial natriuretic peptide (mANP)...
  10. pmc Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats
    Alessandro Cataliotti
    Molecular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Circulation 123:1297-305. 2011
    ..In the current study, we tested the effects of sustained cardiac proBNP gene delivery on BP, cardiac function, and remodeling in spontaneously hypertensive rats (SHR)...
  11. pmc Cardiac micro-computed tomography imaging of the aging coronary vasculature
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Circ Cardiovasc Imaging 5:518-24. 2012
    ....
  12. ncbi request reprint Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure
    Horng H Chen
    Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 288:R1093-7. 2005
    ..Cardiac filling pressures were reduced in all three groups. These studies also support the conclusion that in experimental overt CHF, renal resistance to natriuretic peptides in increasing rank order is BNP<Uro<ANP...
  13. pmc Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension
    Alessandro Cataliotti
    Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Circulation 118:1729-36. 2008
    ..We also sought to establish the ability of this new conjugate to acutely activate cGMP and to reduce blood pressure in an experimental model of angiotensin II (ANG II) -mediated hypertension...
  14. pmc The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects
    Paul M McKie
    Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 55:2140-7. 2010
    ....
  15. doi request reprint Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, MN 55905, USA
    Clin Chem 57:40-7. 2011
    ..The corin gene is expressed in the human heart and kidney, but corin protein expression in the heart, kidney, and circulation, along with whether proBNP is processed by circulating corin, remains unknown...
  16. ncbi request reprint Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure
    Alessandro Cataliotti
    Department of Physiology and Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Circulation 112:836-40. 2005
    ..We hypothesized that novel oral conjugated hBNP (CONJ-hBNP) increases plasma hBNP, activates cGMP, and reduces mean arterial pressure (MAP)...
  17. pmc Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure
    Horng H Chen
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 53:1302-8. 2009
    ..The purpose of this study was to test the hypothesis that local renal delivery of B-type natriuretic peptide (BNP) will overcome renal resistance to BNP without systemic hypotension...
  18. pmc Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure
    Paul M McKie
    Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN, USA
    Hypertension 47:874-80. 2006
    ....
  19. ncbi request reprint Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy
    Paola Belluardo
    Cardiorenal Research Laboratory, 200 First St, SW, Rochester, MN 55905, USA
    Am J Physiol Heart Circ Physiol 291:H1529-35. 2006
    ..The later activation of both forms of BNP may be a late compensatory effect, because it correlates with severity of HTN rather than cardiac hypertrophy/remodeling...
  20. ncbi request reprint Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators
    Fernando L Martin
    Division of Cardiovascular Diseases, Cardiorenal Research Laboratory, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Rev Cardiovasc Med 9:39-45. 2008
    ..Vasodilators, especially those that are linked to cGMP activation, may provide an alternative approach...